Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy

Protein Engineering, Design & Selection : PEDS
Sheri D MahanMargaret E Black

Abstract

Cytosine deaminase (CD) is currently being used as a suicide gene for cancer gene therapy. The premise of this therapy is the preferential deamination of 5-fluorocytosine (5FC) to 5-fluorouracil by cancer cells expressing cytosine deaminase. However, a lack of efficient gene transfer to tumors combined with inefficient 5FC turnover currently limits the clinical applications of this gene therapy approach. We have used random mutagenesis to create novel bacterial cytosine deaminases that demonstrate an increased preference for 5FC over cytosine. Among the 15 mutants isolated, one conferred sensitivity to Escherichia coli in a negative selection system at a concentration of 5FC that was 10-fold lower than a sublethal dose for wild-type CD. Evaluation of individual substitutions found in this double mutant (Q102R, D314G) demonstrated that the substitution at residue D314 was solely responsible for the observed increase in sensitivity to 5FC. Additional mutagenesis at D314 resulted in the identification of two more substitutions with the ability to confer enhanced 5FC sensitivity to E.coli. Structure determinations of the three CD variants in the presence and absence of a transition state 5FC analogue provide insights to the determi...Continue Reading

Citations

Jun 8, 2012·Applied Biochemistry and Biotechnology·Vinod Kumar YataSiddhartha Sankar Ghosh
May 7, 2011·Biochemistry·Richard S HallFrank M Raushel
Feb 25, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Pingchuan LiAlbert Deisseroth
Jul 14, 2010·Nature Chemical Biology·Gail J BartlettDerek N Woolfson
Sep 21, 2011·Proceedings of the National Academy of Sciences of the United States of America·Chapman M WrightMarc Ostermeier
Nov 11, 2006·BMC Genetics·Jian-Hong Xu, Joachim Messing
Jul 8, 2011·World Journal of Gastroenterology : WJG·Long-Ying DengLi-Zong Shen
Apr 11, 2007·Bioscience, Biotechnology, and Biochemistry·Yoshinori HamajiShun'ichiro Taniguchi
Jan 5, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Brenda F CanineArash Hatefi
Sep 8, 2010·Nanomedicine : Nanotechnology, Biology, and Medicine·Yuhua WangArash Hatefi
Nov 11, 2014·Biochemistry·Daniel S HitchcockFrank M Raushel
Dec 23, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Wing-Fu Lai, Marie Chia-Mi Lin
Aug 11, 2006·Medical Hypotheses·Hassan TirandazAzam Eslamifar
May 20, 2015·The Journal of Gene Medicine·Asif RazaSiddhartha Sankar Ghosh
Sep 24, 2015·PLoS Computational Biology·Noah OllikainenTanja Kortemme
Oct 13, 2009·Nature Methods·Po Hien Ear, Stephen W Michnick
Mar 12, 2015·Acta Crystallographica. Section D, Biological Crystallography·T S PeatC Scott
Oct 24, 2018·Frontiers in Microbiology·Agota AučynaitėJaunius Urbonavičius
Aug 14, 2020·Biochemistry·Soumen DasM G Finn
Dec 19, 2017·Journal of the American Chemical Society·Kristin M BlacklockSagar D Khare
Nov 23, 2006·Journal of the American Chemical Society·Cong LiZaver M Bhujwalla

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.